39plus is a not-for-profit organisation dedicated to providing a new approach to delivering quality care to older people across the 39 postcode region. 39plus offers a range of support services for older people, people with disabilities and their carers.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

PALANTIR AND DEWPOINT THERAPEUTICS ANNOUNCE STRATEGIC PARTNERSHIP

Palantir Technologies Inc. | December 21, 2021

news image

Palantir Technologies Inc. a leading builder of operating systems for the modern enterprise, and Dewpoint Therapeutics the leading biomolecular condensates company, announced a partnership for Palantir’s Foundry platform to help power Dewpoint’s efforts to discover treatments and cures for the most challenging diseases. Palantir Foundry will help to enable researchers at Dewpoint to further their understanding of condensates biology by analyzing lab data along with oth...

Read More

INDUSTRY OUTLOOK

XALUD THERAPEUTICS COMPLETES OVERSUBSCRIBED $30 MILLION SERIES C FINANCING

Xalud Therapeutics | August 25, 2021

news image

Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that it has raised $30 million in a Series C financing. “We are well positioned to continue advancing XT-150, our lead therapeutic candidate, through clinical development and further expand our platform” XT-150 is a locally injectable plasmid DNA gene therapy expressing IL-10v – a proprietary long-acting, mo...

Read More

CELL AND GENE THERAPY

INTEGRAL MOLECULAR INTRODUCES TRANSGENE PROTEIN ENGINEERING PLATFORM TO ADDRESS GENE THERAPY CHALLENGES

Integral Molecular | August 02, 2021

news image

Integral Molecular, the industry leader in membrane proteins, announces the launch of GeneCanvas, its proprietary protein engineering platform to optimize transgenes and other gene therapy elements. GeneCanvas can achieve 10 to 100 fold increases in gene activity by improving transgene protein expression, trafficking, stability, and function. These enhancements will ultimately result in better efficacy, smaller doses, and improved safety for patients. The GeneCanvas...

Read More

INDUSTRIAL IMPACT

CO-DIAGNOSTICS, INC. TO ANNOUNCE EXPANSION OF OEM AGREEMENT WITH BIO MOLECULAR SYSTEMS AT AACC

Co-Diagnostics | July 27, 2022

news image

Co-Diagnostics, Inc. a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be disclosing the global expansion of its OEM agreement with Bio Molecular Systems (BMS) at the Company's customer and distributor update today at AACC. Located in the Gold Coast area of Queensland, Australia, BMS includes the founders and senior personnel from the company responsible for inventing and developing ...

Read More
news image

INDUSTRIAL IMPACT

PALANTIR AND DEWPOINT THERAPEUTICS ANNOUNCE STRATEGIC PARTNERSHIP

Palantir Technologies Inc. | December 21, 2021

Palantir Technologies Inc. a leading builder of operating systems for the modern enterprise, and Dewpoint Therapeutics the leading biomolecular condensates company, announced a partnership for Palantir’s Foundry platform to help power Dewpoint’s efforts to discover treatments and cures for the most challenging diseases. Palantir Foundry will help to enable researchers at Dewpoint to further their understanding of condensates biology by analyzing lab data along with oth...

Read More
news image

INDUSTRY OUTLOOK

XALUD THERAPEUTICS COMPLETES OVERSUBSCRIBED $30 MILLION SERIES C FINANCING

Xalud Therapeutics | August 25, 2021

Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that it has raised $30 million in a Series C financing. “We are well positioned to continue advancing XT-150, our lead therapeutic candidate, through clinical development and further expand our platform” XT-150 is a locally injectable plasmid DNA gene therapy expressing IL-10v – a proprietary long-acting, mo...

Read More
news image

CELL AND GENE THERAPY

INTEGRAL MOLECULAR INTRODUCES TRANSGENE PROTEIN ENGINEERING PLATFORM TO ADDRESS GENE THERAPY CHALLENGES

Integral Molecular | August 02, 2021

Integral Molecular, the industry leader in membrane proteins, announces the launch of GeneCanvas, its proprietary protein engineering platform to optimize transgenes and other gene therapy elements. GeneCanvas can achieve 10 to 100 fold increases in gene activity by improving transgene protein expression, trafficking, stability, and function. These enhancements will ultimately result in better efficacy, smaller doses, and improved safety for patients. The GeneCanvas...

Read More
news image

INDUSTRIAL IMPACT

CO-DIAGNOSTICS, INC. TO ANNOUNCE EXPANSION OF OEM AGREEMENT WITH BIO MOLECULAR SYSTEMS AT AACC

Co-Diagnostics | July 27, 2022

Co-Diagnostics, Inc. a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be disclosing the global expansion of its OEM agreement with Bio Molecular Systems (BMS) at the Company's customer and distributor update today at AACC. Located in the Gold Coast area of Queensland, Australia, BMS includes the founders and senior personnel from the company responsible for inventing and developing ...

Read More